Feature | July 15, 2011| Dave Fornell

The Latest Developments in Cardiovascular Technology

As part of its efforts to expand integration of intravascular ultrasound (IVUS) image guidance with cath lab treatment devices, Volcano Corp. recently announced a supply agreement with ev3, a Covidien company. Volcano will supply its IVUS technology for use in ev3’s TurboHawk plaque excision (atherectomy) systems.


Volcano developed an IVUS-guided balloon catheter, the Vibe RX, which is available in Europe. The company plans to partner with other vendors to create a line of IVUS-guided therapy solutions.


Integrated FFR/OCT Unveiled
The world’s first system to integrate the functional and anatomical modalities of fractional flow reserve (FFR) and optical coherence tomography (OCT) into one platform was highlighted by St. Jude Medical in May at the Paris Course on Revascularization (EuroPCR) 2011. The Ilumien system enables OCT imaging with the third-generation DragonFly OCT catheter, and FFR measurement through wireless connections, which simplify set-up and measurement through the elimination of connecting cables. The combined technology offers percutaneous coronary intervention (PCI) optimization that helps physicians determine if therapeutic intervention is necessary. The Ilumien is pending European CE mark approval.


FDA Advisory Panel to Review Sapien
A U.S. Food and Drug Administration (FDA) advisory panel is scheduled to review Edwards Lifesciences’ premarket approval (PMA) application for the Sapien transcatheter heart valve on July 20. Edwards submitted a PMA application in the fall of 2010 based on data from the inoperable cohort (Cohort B) of the PARTNER Trial, for approval of this therapy in the treatment of inoperable patients with severe aortic stenosis.  


If cleared for commercial use, it would become the first transcatheter aortic valve replacement device in the United States. Transcatheter valve replacement is expected to eventually replace the current standard of open-heart valve replacement surgery.
So far, only one transcatheter valve has been cleared by the FDA – the Medtronic Melody pulmonary valve, which was cleared under a humanitarian device exemption in early 2010.


Medtronic also entered U.S trials for its CoreValve transcatheter aortic valve in late 2010.


FDA Worried About Japanese Devices
The U.S. Food and Drug Administration (FDA) is warning U.S. medical device vendors to beware of possible safety concerns and radioactive contamination of medical devices and components coming from Japan. The FDA said Japan is a critical participant in the global medical device market, but this industry was heavily impacted by the massive March 11, 2011 earthquake and tsunami. The FDA’s Center for Devices and Radiological Health (CDRH) and Center for Biologics Evaluation and Research (CBER) is raising concerns about possible effects these events may have on medical devices, electronic products and device components intended for the U.S. market
Neither CDRH nor CBER has been notified of any defective product or serious adverse events associated with the use of a device related to this disaster. However, given the extent of the devastation, both have concerns about manufacturing conditions as a result of the disaster that could impact the safety and effectiveness of Japanese medical devices. These concerns include radioactive contamination, use of contaminated water, compromise in sterile products during or after production, compromised reliability of product performance (e.g., electrical connectors, microprocessors, alarms, sensors), and damaged and/or disrupted medical device manufacturing facilities.
To read more, visit www.dicardiology.net/article/fda-worries-about-safety-japanese-medical-devices-following-earthquake-tsunami

2011 Best in KLAS Awards
KLAS announced the release of their highly anticipated “2011 Top 20 Best in KLAS Awards: Medical Equipment & Infrastructure” report. The awards are based on data from customer surveys of hospital and clinic executives, administrators, physicians, nurses, clinicians, and other directors and managers interacting with healthcare equipment and infrastructure solutions. Winners applicable to cardiac imaging included:
• Computed Tomography (CT) - 64-slice+: Toshiba Aquilion One
• Magnetic Resonance (MR) - 3.0T: Siemens Magnetom Verio
• MR - 1.5T: Toshiba Vantage
• Ultrasound - General Imaging: GE Healthcare Logiq E9
• Ultrasound - Cardiovascular: GE Healthcare Vivid E9 and the Toshiba Aplio

Related Content

Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
heart team, hybird OR, structural heart team

The heart team approach was first used on a large scale in the CoreValve and Sapien TAVR trials and helped lead to excellent outcomes in high-risk patients.

Feature | Hybrid OR| February 15, 2017 | Dave Fornell
In the current era of healthcare reform and the push toward evidence-based medicine to both lower costs and improve p
HeartFlow FFRct Analysis, NICE guidance, U.K., United Kingdom, guidelines, stable chest pain
News | CT Angiography (CTA)| February 14, 2017
The National Institute for Health and Care Excellence (NICE) in the United Kingdom recently issued guidance for use of...
 Intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt.  Abraham said these devices are in early stage development with small studies to show proof of concept and demonstrate safety.

The Corvia Intra-atrial shunt device (IASD) lowers left atrial pressure by creating a small left atrial to right atrial shunt. Preliminary clinical studies have shown promise for these types of devices to improve HFpEF patient outcomes.

Feature | Heart Failure| February 10, 2017 | Dave Fornell
In the past few years there have been a number of device therapies developed to treat heart failure (HF).
Sponsored Content | Videos | Heart Failure| February 06, 2017
This video demonstrates how to implant the Revivent TC System to reduce the volume of the left ventricle (LV) in hear
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
Edwards Lifesciences, completes acquisition, Valtech Cardio
News | Heart Valve Technology| January 25, 2017
Edwards Lifesciences Corp. announced that it has closed its acquisition of Valtech Cardio Ltd., developer of the...
SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart| January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
NCDR, ACC, JACC, American College of Cardiology, national trends, heart disease treatments, trends in cardiovascular care
News | Cath Lab| January 23, 2017
January 23, 2017 — Over 93 percent of heart attack patients are receiving stents within the guideline-recommended thr
Overlay Init